TW200848058A - Compounds for the treatment of hepatitis C - Google Patents

Compounds for the treatment of hepatitis C Download PDF

Info

Publication number
TW200848058A
TW200848058A TW097108906A TW97108906A TW200848058A TW 200848058 A TW200848058 A TW 200848058A TW 097108906 A TW097108906 A TW 097108906A TW 97108906 A TW97108906 A TW 97108906A TW 200848058 A TW200848058 A TW 200848058A
Authority
TW
Taiwan
Prior art keywords
alkyl
group
hcv
cyclohexyl
hydrogen
Prior art date
Application number
TW097108906A
Other languages
English (en)
Chinese (zh)
Inventor
Robert G Gentles
xiao-fan Zheng
Min Ding
Yong Tu
Ying Han
Piyasena Hewawasam
John F Kadow
John A Bender
Kap-Sun Yeung
Katharine A Grant-Young
Thomas W Hudyma
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of TW200848058A publication Critical patent/TW200848058A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW097108906A 2007-03-14 2008-03-13 Compounds for the treatment of hepatitis C TW200848058A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89488707P 2007-03-14 2007-03-14
US98947407P 2007-11-21 2007-11-21

Publications (1)

Publication Number Publication Date
TW200848058A true TW200848058A (en) 2008-12-16

Family

ID=39477552

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097108906A TW200848058A (en) 2007-03-14 2008-03-13 Compounds for the treatment of hepatitis C

Country Status (19)

Country Link
US (1) US7547690B2 (enExample)
EP (1) EP2118109B1 (enExample)
JP (1) JP5232178B2 (enExample)
KR (1) KR20100015304A (enExample)
CN (1) CN101657455B (enExample)
AR (1) AR065772A1 (enExample)
AU (1) AU2008226639B2 (enExample)
BR (1) BRPI0808763A2 (enExample)
CA (1) CA2681093A1 (enExample)
CL (1) CL2008000751A1 (enExample)
CO (1) CO6180426A2 (enExample)
EA (1) EA016614B1 (enExample)
IL (1) IL200905A0 (enExample)
MX (1) MX2009009473A (enExample)
NZ (1) NZ579342A (enExample)
PE (1) PE20090648A1 (enExample)
TW (1) TW200848058A (enExample)
WO (1) WO2008112473A1 (enExample)
ZA (1) ZA200906129B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1688420A4 (en) * 2003-11-19 2008-10-22 Japan Tobacco Inc 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
PL2209789T3 (pl) * 2007-11-20 2012-04-30 Bristol Myers Squibb Co Skondensowane z cyklopropylem indolobenzoazepinowe inhibitory NS5B HCV
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
AU2008339917B2 (en) 2007-12-24 2013-02-07 Tibotec Pharmaceuticals Macrocyclic indoles as hepatitis C virus inhibitors
EP2280978B1 (en) * 2008-03-27 2013-04-24 Bristol-Myers Squibb Company Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors
US8178523B2 (en) * 2008-03-27 2012-05-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8138171B2 (en) * 2008-03-27 2012-03-20 Bristol-Myers Squibb Company Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
BR112012013765A2 (pt) 2009-12-07 2016-04-26 Targacept Inc 3,6-diazabiciclo[3.1.1] heptanos como ligantes de receptor nicotínico neuronal de acetilcolina
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
WO2014011863A1 (en) * 2012-07-12 2014-01-16 Targacept, Inc. Method of treatment with 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane
AU2013290402A1 (en) * 2012-07-18 2015-03-05 Bristol-Myers Squibb Holdings Ireland Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1 r,5s) -3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide
JP2019510020A (ja) 2016-03-15 2019-04-11 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 害虫を防除するための置換スルホニルアミド類
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
CN110028510A (zh) * 2019-05-22 2019-07-19 南京合巨药业有限公司 一种3-甲基-3,6-二氮杂-双环[3,1,1]庚烷二盐酸盐的制备方法
KR20220098170A (ko) 2019-11-07 2022-07-11 바이엘 악티엔게젤샤프트 동물 해충 방제를 위한 치환된 술포닐 아미드
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005013922D1 (de) 2004-02-24 2009-05-28 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
AU2005298403A1 (en) 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521442B2 (en) 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN101490054B (zh) 2006-05-25 2012-05-16 百时美施贵宝公司 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

Also Published As

Publication number Publication date
EA200901241A1 (ru) 2010-02-26
AU2008226639B2 (en) 2012-07-19
KR20100015304A (ko) 2010-02-12
ZA200906129B (en) 2010-11-24
CN101657455B (zh) 2013-02-06
EP2118109B1 (en) 2014-11-26
CN101657455A (zh) 2010-02-24
AR065772A1 (es) 2009-07-01
BRPI0808763A2 (pt) 2014-09-16
JP2010521476A (ja) 2010-06-24
WO2008112473A1 (en) 2008-09-18
EA016614B1 (ru) 2012-06-29
PE20090648A1 (es) 2009-05-29
US7547690B2 (en) 2009-06-16
IL200905A0 (en) 2010-05-17
JP5232178B2 (ja) 2013-07-10
EP2118109A1 (en) 2009-11-18
CL2008000751A1 (es) 2008-07-25
MX2009009473A (es) 2009-09-15
CO6180426A2 (es) 2010-07-19
AU2008226639A1 (en) 2008-09-18
US20080227769A1 (en) 2008-09-18
CA2681093A1 (en) 2008-09-18
NZ579342A (en) 2011-07-29

Similar Documents

Publication Publication Date Title
TW200848058A (en) Compounds for the treatment of hepatitis C
CN101918410B (zh) 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
EP2024375B1 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
CN101730698B (zh) 用于治疗丙型肝炎的化合物
US7521443B2 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US8129367B2 (en) Compounds for the treatment of Hepatitis C
JP2010521483A (ja) シクロプロピル縮合インドロベンゾアゼピンhcvインヒビター
TW200906418A (en) Compounds for the treatment of hepatitis C
CN101646674B (zh) 用于治疗丙型肝炎的吲哚并苯并氮杂*衍生物
CN101443336B (zh) 环丙基稠合的[吲哚]并[苯并氮杂*]hcv ns5b抑制剂
ES2360737T3 (es) Inhibidores de ns5b del vhc de indolobenzazepina condensados con ciclopropilo.
HK1122814B (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors